1	Differences in sensory nerve block between						
2	levobupivacaine and bupivacaine at low concentrations						
3	in humans and animals						
4							
5	Short title: Selective block of nociceptive stimuli by levobupivacaine						
6							
7	Akiyuki Sakamoto ^{1,2*} , Satoshi Tanaka ¹ , Takashi Ishida ¹ Mikito Kawamata ¹						
8							
9	¹ Department of Anesthesiology and Resusitology, Shinshu University School of						
10	Medicine, Matsumoto 390-8621, Japan.						
11	² Shinonoi General Hospital the Department of Anesthesiology, Nagano 388-8004,						
12	Japan.						
13							
14	* Corresponding author						
15	E-mail: <u>akiyuki@shinonoi-hp.jp</u> (AS)						
16							
17	Author contributions						
18	Data curation: T Ishida; Formal analysis: T Ishida, Funding acquisition: A Sakamoto;						
19	Investigation: A Sakamoto, S Tanaka; Methodology: S Tanaka; Project administration:						
20	A Sakamoto; Resources: A Sakamoto; Software: T Ishida; Validation: S Tanaka;						
21	Visualization: A Sakamoto; Writing - original draft: A Sakamoto; Writing - review &						
22	editing: S Tanaka, T Ishida, M Kawamata						

23 Abstract

Physiochemical properties of levobupivacaine and bupivacaine are identical, but 24 pharmacokinetic and pharmacodynamics properties differ due to stereoselective 25 26 interactions at the molecular sites of action. An evaluation of nerve block characteristicsis 27 essential for optimal clinical application. This study compared the sensory blocking 28 characteristics of levobupivacaine to bupivacaine in humans and model animals. 29 Levobupivacaine and bupivacaine were compared for sensory block efficacy using a randomized, double-blinded, crossover study design. Eighteen healthy volunteers were 30 randomized to receive levobupivacaine or bupivacaine by subcutaneous injection into the 31 32 forearm, followed by the other drug 1 week later with injection order counterbalanced 33 across subjects. Tactile detection and mechanical pain thresholds were determined using 34 von Frey hairs and thermal pain threshold using a thermal stimulator. Effects of levobupivacaine and bupivacaine, on the spiking activity of spinal dorsal horn (SDH) 35 36 neurons evoked by innocuous or noxious stimuli were also compared in anesthetized 37 Sprague–Dawley rats by in vivo extracellular recordings. There were no significant 38 differences in mechanical and thermal pain thresholds following levobupivacaine or bupivacaine injection at 0.025%, 0.0625%, and 0.125%. There was also no significant 39 40 difference in tactile detection threshold following levobupivacaine or bupivacaine 41 injection at 0.125%. However, tactile detection threshold was significantly higher after 42 administration of bupivacaine at 0.025% and 0.0625% compared to equivalent doses of 43 levobupivacaine. Subcutaneous injection of bupivacaine at 0.05% also induced 44 significantly greater inhibition of SDH neuron spiking activity evoked by innocuous 45 stimuli compared to an equivalent dose of levobupivacaine, while there was no significant

46	difference in suppression of spiking activity evoked by noxious stimuli. Low-dose
47	bupivacaine induces greater suppression tactile sensation than low-dose levobupivacaine.
48	Thus, low-dose levobupivacaine demonstrates relatively greater blocking selectivity for
49	noxious over innocuous stimuli compared to low-dose bupivacaine. Levobupivacaine
50	may be advantageous for applications where pain must be suppressed but non-nociceptive
51	sensations maintained.

53 Introduction

Bupivacaine is a long-acting local anesthetic that has been used clinically for several 54 decades as a racemic mixture (50:50) of dextrorotatory R-(+)- and levorotatory S-(-)-55 56 isomers. However, the R-(+)-isomer may contribute disproportionately to adverse effects on the nervous and cardiovascular systems than the S-(-)-isomer [1-5]. Therefore, 57 58 levobupiyacaine, the pure S-(-)-isomer of bupiyacaine, has been introduced into clinical 59 practice as a safer alternative. Although the physiochemical properties of levobupivacaine and bupivacaine are identical, they differ in pharmacokinetic and pharmacodynamics 60 properties due to stereoselective interactions at molecular targets [4-6]. 61

62 Local anesthetics at sufficient concentrations can prevent impulse transmission by 63 all types of peripheral nerves, resulting in motor blockade and sensory blockade for both 64 noxious and innocuous stimuli. Complete block of motor and sensory transmission is generally beneficial during surgery, while nociceptive-specific block without motor 65 paralysis or loss of innocuous sensation is often desirable in the post-operative period to 66 67 facilitate earlier mobilization. The motor-blocking potency of levobupivacaine is lower than that of bupivacaine at the same concentration and amount when administered by 68 intrathecal and epidural routes [5, 7-10]. Recently, Uta and colleagues reported that 69 70 levobupivacaine also potently inhibits $A\delta$ - and C-fiber transmission but requires a 71 higher dose to suppress A β fiber transmission compared to bupivacaine as evidenced by whole cell patch-clamp recordings from rat spinal dorsal horn (SDH) neurons [11]. 72 73 Nerve fibers of the A β -type transmit tactile and pressure sensations, whereas A δ - and C-74 fibers transmit nociception from noxious stimuli [12]. Therefore, we hypothesized that 75 levobupivacaine would produce greater nociceptive-specific block than bupivacaine, a

76 property especially useful in the outpatient surgery setting. However, these differential

- 77 blocking properties have not been confirmed in vivo.
- 78 It is of great importance to characterize the sensory block characteristics of bupivacaine
- and levobupivacaine for optimal clinical applications. The purpose of the present study
- 80 was to compare the relatively selectivity of racemic bupivacaine to levobupivacaine for
- 81 pain sensation and tactile sensation block by measuring sensory thresholds in human
- 82 volunteers and the spiking activity of SDH neurons in response to noxious and innocuous
- 83 cutaneous stimuli by in vivo single unit extracellular recordings in anesthetized rats.

85 Materials and methods

This study consists of two parts. In Experiment (1), we compared the effects of levobupivacaine to bupivacaine on the tactile detection threshold and both mechanical and thermal pain sensation thresholds following subcutaneous administration in healthy human volunteers. In Experiment (2), the effects of subcutaneous levobupivacaine and bupivacaine administration were compared for suppression of SDH neuron activity evoked by innocuous and noxious stimuli in anesthetized rats.

92

93 Experiment (1): Effects of subcutaneous levobupivacaine and

94 **bupivacaine on human sensory thresholds**

95 Subjects

Experiment (1) was conducted in accordance with the principles outlined in the 96 97 Declaration of Helsinki and the ethical guidelines for pain research in humans of the 98 International Association for Study of Pain. All protocols were approved by the Ethics 99 Committee of Shinshu University School of Medicine, Matsumoto, Japan (document number: 3252) on October 8, 2015. Experiment (1) was also registered with the 100 101 University Hospital Medical Information Network in Japan (number UMIN000019307) 102 on October 10, 2015. Recruitment for the study ran from October 13, 2015 to February 103 15, 2018 and conducted from October 18, 2015 to March 3, 2018 at Shinshu University 104 Hospital, Matsumoto, Japan. Written informed consent was obtained from each subject 105 before testing. A randomized, double-blinded, crossover design was implemented to 106 compare different subcutaneous doses of levobupivacaine and bupivacaine without bias.

Eighteen volunteers (15 male and 3 female) aged 23–46 years old were recruited at Shinshu University School of Medicine. Inclusion criteria were 20 years of age or older and willing to provide informed consent. Exclusion criteria were analgesic allergies, drug or alcohol abuse, diabetes, neuromuscular diseases, chronic pain, and daily use of analgesics.

112

113 Study protocol

114 A CONSORT diagram of study enrolment is presented in Fig 1. The 18 volunteers were 115 randomly assigned to receive either levobupivacaine in the first period followed by 116 bupivacaine in the second period or bupivacaine in the first period followed by 117 levobupivacaine in the second period at a 1:1 ratio (crossover design). Volunteers were 118 randomized to the levobupivacaine-first or bupivacaine-first group using the random 119 generation function in Microsoft Excel with a permuted random block size of 6. Subjects 120 were further randomly divided into three dose groups receiving 0.125%, 0.0625%, or 121 0.025% injections. These groups were administered the same dose of the other local 122 anesthetic after a 1-week washout period. The commercial 0.5% bupivacaine preparation 123 Marcaine[®] (AstraZeneca KK, Osaka, Japan) and the 0.5% levobupivacaine preparation 124 Popscaine[®] (Maruishi, Tokyo, Japan) were diluted in sterile normal saline on the test day to yielded the 0.125%, 0.0625%, or 0.025% solutions for subcutaneous injection. Freshly 125 126 prepared solutions were injected into the anterior aspect of the left forearm at a volume 127 of 3 mL using a 25-gage needle under ultrasound guidance (S-NerveTM, SonoSite Japan 128 KK., Tokyo, Japan). The tactile detection threshold (TDT) and mechanical pain threshold 129 (MPT) were determined at the center of the injected area by applying von Frey (vF) hairs of increasing stiffness (force). The TDT was measured from a baseline force of 0.16 g 130

131 and MPT from a baseline of 6 g. Participants were instructed to announce when touch 132 was first detected (TDT) and when the stimulus became painful (MPT). Each threshold 133 was measured three times at intervals of 10 s, and the median value was recorded for 134 analyses. The thermal pain threshold (TPT) was measured using a thermal stimulator 135 (THERMAL STIMULATOR®, Dia-medical Co., Tokyo, Japan). The thermode, a Peltier 136 element covered by a ceramic contact plate ($6 \text{ mm} \times 6 \text{ mm}$), was heated at a rate of 1.0°C/s 137 from a baseline temperature of 32°C to a maximum of 47°C to prevent injury. Participants 138 were instructed to notify when thermal pain sensation was detected. Evaluators of these 139 sensory thresholds were blinded to the anesthetic administered. Measurements were 140 performed before injection and 5, 15, 30, 45, and 60 min after injection in a quiet room 141 with controlled ambient temperature $(22^{\circ}C-24^{\circ}C)$ (Fig 2).

142

143 Fig 1. CONSORT diagram illustrating the flow of participants through each phase

144 of the randomized crossover trial

145 Fig 2. Schematic diagram of Experiment (1) in humans.

Tactile and mechanical pain thresholds were determined using von Frey (vF) hairs applied for 5 s, while thermal pain threshold was measured using a thermal stimulator (THERMAL STIMULATOR®, Dia-medical Co., Tokyo, Japan) heated at 1°C/min from 32°C to a maximum of 47°C. All thresholds were measured at baseline and again at the same site and times following subcutaneous injection of local anesthetic (LA).

151

To control for possible carryover effects from one injection to the next, the total scores for each period were compared between two sequence groups using an independent samples t-test. Furthermore, the effect of each period was examined by comparing the

thresholds in the first period with the thresholds in the second period using paired-samplet-tests [13].

157

158 Experiment (2): Effects of subcutaneous levobupivacaine and

159 bupivacaine on spinal dorsal horn transmission in anesthetized

160 **rats**

161 All animal care and study protocols were approved by the Shinshu University School of

162 Medicine Animal Care and Use Committee (no. 021118) and conducted in accordance

163 with the guidelines of the National Institutes of Health. Seven-week-old male Sprague-

164 Dawley rats weighing 180–220 g were housed under controlled temperature (22–23°C),

humidity 40%–60%, and light/dark cycle (12-hour/12-hour) with ad libitum access to

166 food and water.

167 Prior to neuronal recordings, rats were anesthetized with 3% sevoflurane in oxygen. 168 A middle vertical incision was made over the dorsum and the underlying paraspinous 169 musculature was detached from the spinous processes and dorsal aspects of vertebrae from T10 to L3. Dorsal laminectomies were performed across T12-L1 to expose the 170 171 lumber intumescence. The rat was then placed into a stereotaxic frame (Model ST-7, 172 Narishige, Tokyo, Japan) and secured using vertebral clamps and ear bars. After removing 173 the dura, the surface of the spinal cord was irrigated at 10 mL/min with Kreb's solution 174 (in mM, NaCl, 117; KCl, 3.6; CaCl₂, 1.2; NaH₂PO₄, 1.2; glucose, 11; NaHCO₃, 25 mM) aerated with 95% O₂-5% CO₂. Body temperature was maintained at 36°C-38°C using an 175 176infrared heat lamp and thermo-controlled heat pad based on feedback from a rectal

177 thermometer.

Extracellular recordings from single neurons were acquired using a tungsten 178 179 electrode (10–12 M Ω ; FHC Inc., Brunswick, ME) inserted in the deep dorsal horn of the 180 lumbar spinal cord. We identified neurons (single units) according to the mechanical 181 receptive fields (RF) of the hindpaw. Extracellular action potentials were amplified 182 (×20000-50000), band-pass filtered between 300-3000 Hz, digitized (CED 1401; 183 Cambridge Electronic Design, Cambridge, UK), and stored on an IBM-AT personal 184 computer (Think Pad; IBM Japan, Tokyo). Spike trains were analyzed using Spike 2 185 (Cambridge Electronic Design).

186 Neurons that responded to both an innocuous stimulus (light touch with a camel-hair brush) and a noxious stimulus (pinch force of 250 g/mm² using an arterial clip) were 187 188 classified as wide-dynamic-range (WDR), those responsive to noxious but not non-189 noxious stimuli as high-threshold, and those responsive to low- but not high-intensity 190 stimulation as low-threshold (LT). Only WDR and LT neurons were examined in this 191 study. Consistent with previous reports, all WDR neurons included in the analysis 192 responded to greater stimulus intensities with a graded increase in spike frequency [14], 193 while LT neurons responded only to light mechanical (innocuous) stimuli from a 10 g or 194 lighter vF hair [15]. Therefore, the pinch stimulus was used throughout as a strong 195 noxious stimulus and a 10 g vF hair as a weak noxious stimulus. The responses of 196 individual WDR neurons to stimulation by 4 g and 10 g vF hairs, a brush, and pinch at 197 the center of the RF were recorded in order. Similarly, the responses of LT neurons to 198 stimulation by a 4 g vF hair and a brush at the center of the RF were recorded in order. 199 For measurement of levobupivacaine and bupivacaine effects on these responses, rats 200 were randomly allocated to receive a 500-microL subcutaneous injection of 0.05%

levobupivacaine, 0.05% bupivacaine, or equal-volume saline using a 30-gage needle
targeted to the center of the RF. The responses to punctate mechanical stimulation using
4 or 10 g vF hairs with sufficient force to bend the hairs for 5 s were recorded.
Additionally, the responses to one stroke from a camel-hair brush and a pinch stimulation
from an arterial clip for 5 s were recorded. The neuronal responses to mechanical stimuli
were recorded 5, 10, 20, 30, 60, and 90 min after injection by investigators blinded to
group allocation (levobupivacaine, bupivacaine, or saline).

208

209 Statistical analyses

210 Prior to Experiment (1), a statistical power analysis was performed using G*Power, 211 version 3.1, with TDT as the primary outcome. Wallace and coworkers reported a TDT 212 of 3.86 ± 0.38 mN (mean \pm SD) at the arm [16]. Therefore, when levobupivacaine does 213 not change TDT while bupivacaine increases TDT by 20% at the same concentration, a 214 sample size of 6 is required for a type I error of 0.05 and power of 0.8. As we tested three 215 doses (0.125%, 0.0625%, and 0.025%), 18 people were recruited. Mean responses in each 216 group were first log-transformed. Results are presented as box-and-whisker plots showing 217 the median with first and third quartiles as well as the 10th and 90th percentiles. Baseline 218 responses were compared among groups using the Kruskal-Wallis H-test with Dunn's post-hoc tests for multiple comparisons, while anesthesia-induced changes were 219 220 compared by Mann-Whitney U-test with Bonferroni correction for multiple comparisons. 221 The sample size calculation for Experiment (2) was based on a previous study recording 222 changes in the firing rates of SDH neurons evoked by local anesthetics in anesthetized 223 animals [17]. All data are presented as mean \pm SD. Baseline firing frequencies were

224	compared	among	groups	by	Kruskal–Wallis	H-test	with	Dunn's	post-hoc	tests	for
-----	----------	-------	--------	----	----------------	--------	------	--------	----------	-------	-----

- 225 pairwise comparisons, while changes induced by bupivacaine and levobupivacaine were
- 226 compared by Mann–Whitney U-test with Bonferroni correction. All statistical analyses
- 227 were performed using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA).
- For all statistical tests, P < 0.05 (two-tailed) was considered statistically significant.

230 **Results**

Experiment (1): Subcutaneous injection of low-dose bupivacaine induced greater suppression of tactile sensation

233 than low-dose levobupivacaine in human volunteers

234 **Patient characteristics**

- All 18 healthy volunteers completed the study without major side effects. Demographic
- characteristics are summarized in Table 1.

	male	female	total
N	15	3	18
Age (y.o.)	33 ± 7	27 ± 4	32 ± 7
Height (cm)	169 ± 6	155 ± 10	167 ± 9
Weight (kg)	65 ± 13	45 ± 9	61 ± 15

237 **Table 1. Demographic characteristics of human volunteers**

238 Data are presented as mean \pm standard deviation.

239 Carryover and period effects

There were no significant differences in baseline TDT, MPT, and TPT, and no significant differences in threshold changes at 15 min post-administration between periods and anesthetics at equivalent doses (Supplementary Table S1), indicating that changes in TDT, MPT, and TPT induced by bupivacaine or levobupivacaine administration in the first period had disappeared by the start of the second period. Therefore, pooled data from the first and second periods were used to investigate the effects of levobupivacaine and bupivacaine on all outcomes.

247

248 Effects of levobupivacaine and bupivacaine on sensory thresholds

249 There were no significant differences in the TDT (Fig 3A), MPT (Fig 3B), and TPT (Fig

- 3C) at baseline between anesthetic groups. As expected, TDT increased significantly after
 subcutaneous administration of both levobupivacaine and bupivacaine at concentrations
 of 0.125%, 0.0625%, and 0.025%. There was no significant difference in TDT between
- anesthetic groups at 0.125%. However, TDT was significantly higher 5 and 15 min after
- subcutaneous administration of 0.0625% bupivacaine compared to the same
- levobupivacaine concentration at 5 and 15 min post-injection (P = 0.029 and P = 0.026),

and 5, 15, 30 and 45 min after administration of 0.025% bupivacaine compared to the

same levobupivacaine concentration and post-administration times (P = 0.002, P = 0.002,

P = 0.002, and P = 0.026, respectively). Both levobupivacaine and bupivacaine also significantly increased the MPT at all concentrations tested as quantified by mean vF hair

force, and the TPT produced by contact heat at 5 min after injection compared to before injection, without significant differences between drugs at equivalent concentrations and post-injection times (Figs 3B and 3C).

263

Fig 3. Changes in tactile and pain thresholds in human volunteers following

subcutaneous bupivacaine and levobupivacaine injections.

266 (A, B) Tactile detection threshold (TDT) (A) and mechanical pain threshold (MPT) (B)

267 measured using von Frey hairs. (C) Thermal pain threshold (TPT) measured by a

- thermal stimulator. The TDT was significantly higher (tactile response less sensitive)
- following bupivacaine injection at concentrations of 0.025% and 0.0625% compared to
- 270 equal-dose levobupivacaine (A), while MPT and TPT did not differ between LAs at any

271	concentrations tested (B, C). Arrows indicate the cutoffs (B, C), and the dotted line
272	indicates the baseline level (A, B). $*P < 0.05$ between bupivacaine and
273	levobupivacaine, # $P < 0.05$ vs. baseline.
274	
275	Experiment (2): Subcutaneous injection of bupivacaine
276	induced greater suppression of SDH neuron activity evoked by
277	innocuous stimulation than equal-dose levobupivacaine in
278	anesthetized rats
279	A total of 37 neurons were identified from the T13 to L1 SDH of 37 anesthetized rats, of
280	which 19 were classified as WDR and the remaining 18 as LT neurons. Of these, complete
281	baseline and post-injection spike recordings were obtained from 13 WDR and 13 LT
282	neurons for analysis. The average of depth of the electrode tip position below the dorsal
283	spinal cord surface was $745 \pm 103 \mu\text{m}$ for WDR neurons and $432 \pm 70 \mu\text{m}$ for LT neurons,

284 consistent with the known anatomic distribution.

285 Effects of bupivacaine and levobupivacaine on WDR neuron activity

evoked by innocuous and noxious stimuli

Figs 4A and 5A show typical spike discharge patterns of WDR neurons in response to noxious stimuli (pinch and 10 g vF hair) and innocuous mechanical stimuli (brush and 4 g vF hair) within corresponding receptive fields at baseline and 10, 30, and 60 min after subcutaneous administration of levobupivacaine or bupivacaine, respectively, while Figs 4B and 5B show the mean changes. Both levobupivacaine and bupivacaine at 0.05% significantly inhibited the spiking responses of WDR neurons induced by noxious stimuli

without significant difference (Fig 4B). However, the inhibitory effects of bupivacaine on the responses of WDR neurons to (innocuous) brush and 4 g vF between 10 and 60 min were significantly stronger than those of levobupivacaine (brush, 5 min P = 0.016, 10 min P = 0.016, 20 min P = 0.008, 30 min P = 0.008, 60 min P = 0.016; 4g vF, 20 min P = 0.032, 30 min P = 0.008, 60 min P = 0.008) (Fig 5B), consistent with the effects observed on tactile thresholds in humans.

299

```
300 Fig 4. Both bupivacaine and levobupivacaine strongly suppressed the spiking
```

301 responses of wide dynamic-range neurons to noxious stimuli in anesthetized rats.

302 (A) Typical spiking responses of wide dynamic-range (WDR) neurons to noxious

303 stimuli (pinch and 10 g von Frey hair) at baseline and after subcutaneous administration

304 of bupivacaine or levobupivacaine (both 0.05%). (B) Mean changes in spiking response

305 to noxious stimuli after subcutaneous administration of bupivacaine (n = 5),

$$306$$
 levobupivacaine (n = 5), and saline (n = 3)

307

Fig 5. Bupivacaine suppressed the spiking response of wide-dynamic-range neurons to innocuous stimuli more potently than levobupivacaine in anesthetized rats.

310 (A) Typical responses of wide-dynamic-range (WDR) neurons to innocuous stimuli 311 (brush and 4 g von Frey hair) at baseline and after subcutaneous injection of bupivacaine 312 and levobupivacaine (A). (B) Mean changes in spiking response after subcutaneous 313 injection of bupivacaine (n = 5), levobupivacaine (n = 5), and saline (n = 3). The 314 suppression of firing was stronger after administration of bupivacaine. * P < 0.05

between bupivacaine and levobupivacaine, # P < 0.05 vs. baseline.

316

317 Effects of bupivacaine and levobupivacaine on LT neuron activity in 318 response to innocuous stimuli

319 Fig 6A shows typical discharge patterns of LT neurons in response to innocuous 320 mechanical stimuli (brush and 4 g vF hair) within the corresponding receptive fields at 321 baseline and 10, 30, and 60 min after subcutaneous administration of levobupivacaine or bupivacaine, while Fig 6B shows the mean changes. The mean inhibitory effects of 322 323 bupivacaine on the responses of LT neurons to brush strokes 10-30 min post-injection 324 were significantly stronger than those of levobupivacaine (P = 0.016 at 10 min, P = 0.008325 at 20 min, P = 0.016 at 30 min) (Fig 6B). Similarly, the inhibitory effects of bupivacaine 326 on the responses of LT neurons to 4 g vF at 10 and 20 min post-injection were 327 significantly stronger than those of levobupivacaine (P = 0.032 at 10 min, P = 0.008 at 20 328 min) (Fig 6B), again consistent with the effects observed on tactile thresholds in humans. 329

Fig 6. Bupivacaine suppressed the spiking response of low-threshold neurons to innocuous stimuli more potently than levobupivacaine in anesthetized rats.

332 (A) Typical responses of low-threshold (LT) neurons to innocuous stimuli (brush and 4

333 g von Frey hair) at baseline and after subcutaneous administration of bupivacaine and

levobupivacaine. (B) Mean changes in spiking response after subcutaneous

administration of bupivacaine (n = 5), levobupivacaine (n = 5), and saline (n = 3). The

suppression of firing was stronger after administration of bupivacaine. *P < 0.05

between bupivacaine and levobupivacaine, # P < 0.05 vs. baseline.

339 **Discussion**

The major findings of this study are as follows. (1) In human volunteers, both 0.125% 340 bupivacaine and 0.125% levobupivacaine increased pain and tactile thresholds in 341 342 response to vF hairs and heat stimuli, while 0.025% and 0.0625% levobupivacaine 343 enhanced pain thresholds but not thresholds for detection of innocuous stimuli. In contrast, 344 bupiyacaine at the same low concentrations enhanced thresholds to both noxious and 345 innocuous stimuli. In other words, low-dose bupivacaine suppressed sensation to 346 innocuous stimuli more powerfully than levobupivacaine. (2) In extracellular in vivo recordings from rat SDH neurons, both 0.05% bupivacaine and 0.05% levobupivacaine 347 348 suppressed the spiking responses to noxious stimuli (from a 10 g vF hair and clamping) 349 with equal efficacy similarly. On the other hand, the inhibitory effects of bupivacaine on the responses of LT neurons to 4 g vF were significantly stronger than those of 350 351 levobupivacaine. To our knowledge, this is the first study demonstrating that low 352 concentrations of bupivacaine and levobupivacaine have distinct anesthetic effects in 353 humans, with levobupivacaine suppressing nociceptive mechanical and thermal 354 sensations as effectively as bupivacaine but preserving innocuous tactile sensation. This differential effect on sensation in humans is in accord with the distinct effects of these 355 356 two LAs on the spiking responses of rat SDH neurons to innocuous and noxious stimuli. 357 Thus, this study provides a plausible mechanism for the differential effects of bupivacaine 358 and levobupivacaine on tactile sensation and nociception, and further suggests that low-359 dose levobupivacaine can suppress pain as effectively as bupivacaine but without 360 producing a numbing sensation that may delay post-operative mobilization.

361 Sensory threshold measurements in humans revealed no significant differences

between bupivacaine and levobupivacaine at 0.125%, in accord with previous clinical
studies reporting no significant differences in post-operative pain and motor block
between bupivacaine and levobupivacaine at 0.25% and 0.5% [18, 19]. Indeed, all three
of these doses are above the 95% effective dose (ED₉₅), so no substantial differences are
expected [20, 21]. At lower doses, however, levobupivacaine appears less effective than
bupivacaine for blocking peripheral sensory fibers mediating tactile sensation, but
roughly as effective for blocking nociceptive fibers.

369 The pricking pain sensation caused by stiff von Frey hairs is mainly transmitted by 370 A δ -fibers [22], while the heat pain sensation is transmitted by both A δ - and C-fibers [23]. 371 The tactile sensation from softer von Frey hairs is transmitted by A β -fibers [24]. The SDH 372 contains neurons that respond differently to these inputs, including WDR neurons that 373 respond to stimuli of different intensities, ranging from gentle to painful [25]. Conversely, 374 LT neurons respond only to innocuous stimuli, mainly via A β -fibers [26]. In the present 375 study, 0.025% and 0.0625% levobupivacaine inhibited painful sensation but not tactile 376 sensation in humans, while 0.05% levobupivacaine suppressed WDR neuron responses 377 to noxious stimuli but not LT neuron responses to innocuous stimuli. These results 378 suggest that levobupivacaine at low doses preferentially blocks Aδ- and C-fiber 379 transmission, resulting in greater relative nociceptive-specificity. Uta and colleagues also 380 reported that L-bupivacaine (levobupivacaine) preferentially inhibited the firing of 381 nociceptive neurons, while D-bupivacaine blocked the firing of nociceptive and non-382 nociceptive neurons with roughly equal efficacy as evidenced by electrophysiological analysis of rat dorsal root ganglion neurons in vitro and spinal transmission in vivo [11]. 383 384 Levobupivacaine and bupivacaine are optical isomers with identical dissociation constants, molecular weights, and liposolubility, key factors determining the activities of 385

conventional local anesthetics [27]. Both compounds also target sodium channels. 386 387 However, nine sodium channel subtypes have been identified (Nav 1.1-1.9), so 388 differential fiber block may result from variations in channel subtype block efficacy combined with unique expression patterns among fiber types. Tetrodotoxin (TTX)-389 390 resistant Nav 1.8 and 1.9 are expressed at high levels in (nociceptive) Aδ- and C-fibers 391 [28-30], and it has been reported that levobupivacaine has a higher affinity for TTX-392 resistant than TTX-sensitive sodium channels. In contrast, bupivacaine has shown no 393 difference in affinity between tetrodotoxin-sensitive and tetrodotoxin-resistant sodium 394 channels [11, 31]. Thus, the differences in sensory block characteristics between 395 bupivacaine and levobupivacaine may stem from differential blockade of TTX-sensitive 396 and -resistant voltage-gated sodium channels.

397 Suppression of tactile sensation from innocuous stimuli (a brush and vF 4 g) differed 398 between bupivacaine and levobupivacaine at 0.0625%, a concentration lower than 399 commonly used in clinical practice [1, 32] and thus not fully investigated for sensory 400 blocking properties. The concentration of local anesthetic decreases with distance from 401 the injection site, so an alternative explanation for these results is that the area of tactile 402 sensory block by levobupivacaine is smaller than that by bupivacaine at the same dose 403 and concentration. However, the equal efficacy against nociceptive stimuli mediated by 404 axons within the same fiber bundles suggests that this is unlikely.

The present study has several limitations. First, different noxious stimuli were used in human and rat experiments (thermal vs. pinch) as the thermal stimulator probe was too large for the rat hindpaw. Second, the vF hair stiffness was limited to 300 g and the heat stimulus to 47°C in human experiments to prevent skin damage, which may have also differentially influenced the analgesic effects of bupivacaine and levobupivacaine.

However, the recovery from levobupivacaine analgesia tended to be similar or slower than recovery from bupivacaine (Fig 3). Therefore, it is unlikely that the analgesic efficacy of levobupivacaine is inherently inferior to that of bupivacaine.

413

414 Conclusion

We demonstrate that low-dose levobupivacaine can preferentially block the transmission of nociceptive information without affecting the transmission of innocuous tactile information, while bupivacaine blocks both with roughly equal efficacy. Therefore, levobupivacaine may be a better choice for applications requiring pain suppression but maintenance of tactile sensation.

420

421 Acknowledgments

We would like to thank Dr. Masahiro Sakata (Research Planning & Drug Discovery
Research, Research Laboratories, Maruho Co., LTD.) for technical assistance with the *in vivo* electrophysiological recordings.

425

427 **References**

428 1. Burlacu CL, Buggy DJ. Update on local anesthetics: focus on levobupivacaine.

429 Ther Clin Risk Manag. 2008;4: 381-392. doi: <u>10.2147/tcrm.s1433</u>.

2. Dillane D, Finucane BT. Local anesthetic systemic toxicity. Can J Anesth.
2010;57: 368-380.

432 3. Guinet P, Estebe JP, Ratajczak-Enselme M, Bansard JY, Chevanne F, Bec D, et

al. Electrocardiographic and hemodynamic effects of intravenous infusion of bupivacaine,

434 ropivacaine, levobupivacaine, and lidocaine in anesthetized ewes. Reg Anesth Pain Med.

435 2009;34: 17-23. doi: <u>10.1097/AAP.0b013e31819338e2</u>.

436 4. Tsuchiya H, Ueno T, Mizogami M. Stereostructure-based differences in the
437 interactions of cardiotoxic local anesthetics with cholesterol-containing biomimetic
438 membranes. Bioorg Med Chem. 2011;19: 3410-3415.. doi: <u>10.1016/j.bmc.2011.04.030</u>.

439 5. Heppolette CAA, Brunnen D, Bampoe S, Odor PM. Clinical pharmacokinetics
440 and pharmacodynamics of levobupivacaine. Clin Pharmacokinet. 2020;59: 715-745. doi:
441 10.1007/s40262-020-00868-0.

Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, et al.
Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and
ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the
cardiovascular system. Anesthesiology. 2004;101: 390-398. doi: <u>10.1097/00000542-</u>
200408000-00020.

Atiénzar MC, Palanca JM, Torres F, Borràs R, Gil S, Esteve I. A randomized
comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor
analgesia. Int J Obstet Anesth. 2008;17: 106-111.. doi: <u>10.1016/j.ijoa.2007.10.003</u>.

8. Camorcia M, Capogna G, Berritta C, Columb MO. The relative potencies for
motor block after intrathecal ropivacaine, levobupivacaine, and bupivacaine. Anesth
Analg. 2007;104: 904-907. doi: 10.1213/01.ane.0000256912.54023.79.

453 9. Lacassie HJ, Columb MO. The relative motor blocking potencies of bupivacaine
454 and levobupivacaine in labor. Anesth Analg. 2003;97: 1509-1513.

Hakan Erbay R, Ermumcu O, Hanci V, Atalay H. A comparison of spinal
anesthesia with low-dose hyperbaric levobupivacaine and hyperbaric bupivacaine for
transurethral surgery: a randomized controlled trial. Minerva Anestesiol. 2010;76: 9921001.

Uta D, Koga K, Furue H, Imoto K, Yoshimura M. L-bupivacaine inhibition of
nociceptive transmission in rat peripheral and dorsal horn neurons. Anesthesiology.
2021;134: 88-102. doi: <u>10.1097/ALN.00000000003596</u>.

Price DD, Dubner R, Hu JW. Trigeminothalamic neurons in nucleus caudalis
responsive to tactile, thermal, and nociceptive stimulation of monkey's face. J
Neurophysiol. 1976;39: 936-953. doi: <u>10.1152/jn.1976.39.5.936</u>.

Wellek S, Blettner M. On the proper use of the crossover design in clinical trials:
part 18 of a series on evaluation of scientific publications. Dtsch Ärztebl Int. 2012;109:
276-281. doi: 10.3238/arztebl.2012.0276.

14. Zahn PK, Brennan TJ. Incision-induced changes in receptive field properties of
rat dorsal horn neurons. Anesthesiology. 1999;91: 772-785. doi: <u>10.1097/00000542-</u>
<u>199909000-00030</u>.

15. Reali C, Fossat P, Landry M, Russo RE, Nagy F. Intrinsic membrane properties
of spinal dorsal horn neurones modulate nociceptive information processing in vivo. J
Physiol. 2011;589: 2733-2743.

Wallace MS, Laitin S, Licht D, Yaksh TL. Concentration-effect relations for
intravenous lidocaine infusions in human volunteers: effects on acute sensory thresholds
and capsaicin-evoked hyperpathia. Anesthesiology. 1997;86: 1262-1272. doi:
10.1097/0000542-199706000-00006.

17. Sagar DR, Kendall DA, Chapman V. Inhibition of fatty acid amide hydrolase
produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J
Pharmacol. 2008;155: 1297-1306. doi: <u>10.1038/bjp.2008.335</u>.

18. Ilham C, Bombaci E, Yurtlu S, Çolakoğlu S. Efficiency of levobupivacaine and
bupivacaine for supraclavicular block: a randomized double-blind comparative study.
Braz J Anesthesiol. 2014;64: 177-182

Koch T, Fichtner A, Schwemmer U, Standl T, Volk T, Engelhard K, et al.
Levobupivacaine for epidural anaesthesia and postoperative analgesia in hip surgery: a
multi-center efficacy and safety equivalence study with bupivacaine and ropivacaine.
Anaesthesist. 2008;57: 475-482. doi: <u>10.1007/s00101-008-1357-3</u>.

488 20. Bouvet L, Da-Col X, Chassard D, Daléry F, Ruynat L, Allaouchiche B, et al,

editors. ED₅₀ and ED₉₅ of intrathecal levobupivacaine with opioids for Caesarean
delivery. Br J Anaesth. 2011;106: 215-220.

491 21. Ginosar Y, Mirikatani E, Drover DR, Cohen SE, Riley ET. ED50 and ED95 of

492 intrathecal hyperbaric bupivacaine coadministered with opioids for cesarean delivery.

493 Anesthesiology. 2004;100: 676-682. doi: <u>10.1097/00000542-200403000-00031</u>.

494 22. Beissner F, Brandau A, Henke C, Felden L, Baumgärtner U, Treede RD, et al.

495 Quick discrimination of A(delta) and c fiber mediated pain based on three verbal
496 descriptors. PLOS ONE. 2010;5: e12944.

497 23. Angst MS, Tingle M, Phillips NG, Carvalho B. Determining heat and

498 mechanical pain threshold in inflamed skin of human subjects. J Vis Exp. 2009;23.

- 499 24. Ackerley R, Backlund Wasling H, Liljencrantz J, Olausson H, Johnson RD,
- 500 Wessberg J. Human C-tactile afferents are tuned to the temperature of a skin-stroking
- 501 caress. J Neurosci. 2014;34: 2879-2883. doi: <u>10.1523/jneurosci.2847-13.2014</u>.
- 502 25. Hanai F. Effect of electrical stimulation of peripheral nerves on neuropathic pain.

503 Spine (Phila Pa 1976). 2000;25: 1886-1892. doi: <u>10.1097/00007632-200008010-00005</u>.

50426.Zimmerman A, Bai L, Ginty DD. The gentle touch receptors of mammalian skin.

505 Science. 2014;346: 950-954. doi: <u>10.1126/science.1254229</u>.

- 506 27. Vladimirov M, Nau C, Mok WM, Strichartz G. Potency of bupivacaine 507 stereoisomers tested in vitro and in vivo: biochemical, electrophysiological, and 508 neurobehavioral studies. Anesthesiology. 2000;93: 744-755. doi: <u>10.1097/00000542-</u> 509 200009000-00024.
- Wu Y, Ma H, Zhang F, Zhang C, Zou X, Cao Z. Selective voltage-gated sodium
 channel peptide toxins from animal venom: pharmacological probes and analgesic drug
 development. ACS Chem Neurosci. 2018;9: 187-197.. doi:
 10.1021/acschemneuro.7b00406
- Tsukamoto T, Chiba Y, Wakamori M, Yamada T, Tsunogae S, Cho Y, et al.
 Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium
 channel subtypes (Nav 1.1 to Nav 1.7). Br J Pharmacol. 2017;174: 3881-3892... doi:
 10.1111/bph.13985
- 518 30. Cardoso FC, Lewis RJ. Sodium channels and pain: from toxins to therapies. Br
 519 J Pharmacol. 2018;175: 2138–2157. doi: <u>10.1111/bph.13962</u>.
- 520 31. Oda A, Ohashi H, Komori S, Iida H, Dohi S. Characteristics of ropivacaine block
- of Na+ channels in rat dorsal root ganglion neurons. Anesth Analg. 2000;91: 1213-1220.

522 doi: <u>10.1097/00000539-200011000-00031</u>.

- 523 32. Bajwa SJ, Kaur J. Clinical profile of levobupivacaine in regional anesthesia: A
- 524 systematic review. J Anaesthesiol Clin Pharmacol. 2013;29: 530-539. doi: <u>10.4103/0970-</u>
- 525 <u>9185.119172</u>.

526









#

60

90

#

30

Figure 5

(B)



Levobupivacaine

Bupivacaine

Saline

٠



